Studies of the combination of ABT-199, a BH3 mimetic that specifically targets Bcl-2 in combination with chemotherapy and the proteosome inhibitor bortezomib in "double hit" lymphoma.

被引：1
|
作者：
Bertino, Joseph R.
Johnson-Farley, Nadine
Bhagavathi, Sarathkumar
机构：
[1] Canc Inst New Jersey, New Brunswick, NJ USA
[2] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, New Brunswick, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.e19507
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19507
引用
收藏
页数：1
相关论文
共 28 条
  • [1] ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in "double hit" lymphoma cells
    Johnson-Farley, Nadine
    Veliz, Jonny
    Bhagavathi, S.
    Bertino, Joseph R.
    LEUKEMIA & LYMPHOMA, 2015, 56 (07) : 2146 - 2152
  • [2] Targeting BCL-2 with the BH3 mimetic ABT-199 in ER-positive breast cancer
    Lindeman, G. J.
    Vaillant, F.
    Merino, D.
    Lee, L.
    Breslin, K.
    Pal, B.
    Ritchie, M. E.
    Smyth, G. K.
    Christie, M.
    Phillipson, L. J.
    Burns, C. J.
    Mann, G. B.
    Visvader, J. E.
    CANCER RESEARCH, 2013, 73
  • [3] Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer
    Vaillant, Francois
    Merino, Delphine
    Lee, Lily
    Breslin, Kelsey
    Pal, Bhupinder
    Ritchie, Matthew E.
    Smyth, Gordon K.
    Christie, Michael
    Phillipson, Louisa J.
    Burns, Christopher J.
    Mann, G. Bruce
    Visvader, Jane E.
    Lindeman, Geoffrey J.
    CANCER CELL, 2013, 24 (01) : 120 - 129
  • [4] Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma
    Fresquet, Vicente
    Rieger, Melissa
    Carolis, Carlo
    Garcia-Barchino, Maria J.
    Martinez-Climent, Jose A.
    BLOOD, 2014, 123 (26) : 4111 - 4119
  • [5] The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
    C Touzeau
    C Dousset
    S Le Gouill
    D Sampath
    J D Leverson
    A J Souers
    S Maïga
    M C Béné
    P Moreau
    C Pellat-Deceunynck
    M Amiot
    Leukemia, 2014, 28 : 210 - 212
  • [6] The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
    Touzeau, C.
    Dousset, C.
    Le Gouill, S.
    Sampath, D.
    Leverson, J. D.
    Souers, A. J.
    Maiga, S.
    Bene, M. C.
    Moreau, P.
    Pellat-Deceunynck, C.
    Amiot, M.
    LEUKEMIA, 2014, 28 (01) : 210 - 212
  • [7] BCL-2-Selective BH3 Mimetic ABT-199 Is a Potent Agent For Acute Myeloid Leukemia
    Pan, Rongqing
    Debose, LaKeisha
    Benito, Juliana M.
    Golfman, Leonard S.
    Zweidler-McKay, Patrick A.
    Han, Lina
    Harutyunyan, Karine G.
    Mu, Hong
    Ruvolo, Vivian R.
    Park, Eugene
    Muschen, Markus
    Leverson, Joel
    Borthakur, Gautam
    Kantarjian, Hagop M.
    Ruvolo, Peter P.
    Andreeff, Michael
    Konopleva, Marina
    BLOOD, 2013, 122 (21)
  • [8] COMPLEMENTARY DYNAMIC BH3 PROFILES PREDICT INDUCTION OF APOPTOSIS BY THE MULTI-KINASE INHIBITOR TG02 IN COMBINATION WITH THE BH3 MIMETIC ABT-199 IN AML CELLS
    Burrows, F.
    Pallis, M.
    Ryan, J.
    Seedhouse, C.
    Abdul-Aziz, A.
    Montero, J.
    Letai, A.
    Russell, N.
    HAEMATOLOGICA, 2015, 100 : 354 - 354
  • [9] Targeting the Bcl-2 Family of Proteins in Hodgkin Lymphoma: In Vitro Cytotoxicity, Target Modulation and Drug Combination Studies of the BH3 Mimetic ABT-737
    Jayanthan, Aarthi
    Howard, Scott C.
    Trippett, Tanya
    Horton, Terzah M.
    Daisley, Lara
    Lewis, Victor A.
    Narendran, Aru
    BLOOD, 2008, 112 (11) : 1240 - 1241
  • [10] Bcl-2 overexpression is a predictive biomarker for the combination of ABT-199 with chemotherapy in diffuse large B-cell lymphoma cell lines
    McConnell, Ian
    Anderson, Elyse
    Yazbeck, Victor
    CANCER RESEARCH, 2017, 77
123